[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100586569":3},{"organization":4,"armGroups":7,"interventions":89,"overallOfficials":95,"centralContacts":135,"locations":140,"responsibleParty":356,"collaborators":95,"id":358,"slug":95,"hasResults":359,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":95,"eligibilityCriteria":363,"healthyVolunteers":359,"sex":364,"minAge":365,"maxAge":95,"enrollmentInfo":366,"targetDuration":95,"studyType":369,"phases":370,"briefSummary":372,"conditions":373,"keywords":388,"overallStatus":143,"whyStopped":95,"lastUpdateSubmitDate":400,"lastUpdatePostDateStruct":401,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":409},{"fullName":5,"class":6},"TheRas, Inc., d\u002Fb\u002Fa BBOT (BridgeBio Oncology Therapeutics)","INDUSTRY",[8,14,19,25,31,36,40,44,49,55,59,62,65,68,71,74,77,80,83,86],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1a - Dose Escalation Monotherapy","EXPERIMENTAL","Participants enrolled in this cohort will receive BBO-11818 as monotherapy",[13],"Drug: BBO-11818",{"label":15,"type":10,"description":16,"interventionNames":17},"Cohort 1b - Dose Escalation Combination Therapy (Pembrolizumab)","Participants enrolled in this cohort will receive BBO-11818 in combination with pembrolizumab infusion (IV)",[13,18],"Drug: Pembrolizumab",{"label":20,"type":10,"description":21,"interventionNames":22},"Cohort 1c - Dose Escalation Combination Therapy (Pembrolizumab + Cis\u002Fcarboplatin + Pemetrexed)","Participants enrolled in this cohort will receive BBO-11818 in combination with pembrolizumab infusion (IV), cis\u002Fcarboplatin infusion (IV), and pemetrexed infusion (IV)",[13,18,23,24],"Drug: Platinum chemotherapy (cisplatin or carboplatin)","Drug: Pemetrexed",{"label":26,"type":10,"description":27,"interventionNames":28},"Cohort 1d - Dose Escalation Combination Therapy (Cetuximab ± mFOLFOX6)","Participants enrolled in this cohort will receive BBO-11818 in combination with cetuximab infusion (IV) with or without mFOLFOX6 infusion (IV)",[13,29,30],"Drug: Cetuximab","Drug: mFOLFOX6",{"label":32,"type":10,"description":33,"interventionNames":34},"Cohort 1e - Dose Escalation Combination Therapy (BBO-10203 + mFOLFOX6)","Participants enrolled in this cohort will receive BBO-11818 in combination with BBO-10203 and mFOLFOX6 infusion (IV)",[13,30,35],"Drug: BBO-10203",{"label":37,"type":10,"description":38,"interventionNames":39},"Cohort 1f - Dose Escalation Combination Therapy (BBO-10203 + Cetuximab)","Participants enrolled in this cohort will receive BBO-11818 in combination with BBO-10203 and cetuximab infusion (IV)",[13,29,35],{"label":41,"type":10,"description":42,"interventionNames":43},"Cohort 1g - Dose Escalation Combination Therapy (Cetuximab)","Participants enrolled in this cohort will receive BBO-11818 in combination with cetuximab infusion (IV)",[13,29],{"label":45,"type":10,"description":46,"interventionNames":47},"Cohort 1h - Dose Escalation Combination Therapy (mFOLFIRINOX)","Participants enrolled in this cohort will receive BBO-11818 in combination with mFOLFIRINOX infusion (IV)",[13,48],"Drug: mFOLFIRINOX",{"label":50,"type":10,"description":51,"interventionNames":52},"Cohort 1i - Dose Escalation Combination Therapy (Gemcitabine + Nab-paclitaxel)","Participants enrolled in this cohort will receive BBO-11818 in combination with gemcitabine infusion (IV) and nab-paclitaxel infusion (IV)",[13,53,54],"Drug: Gemcitabine","Drug: Nab-paclitaxel",{"label":56,"type":10,"description":57,"interventionNames":58},"Cohort 1j - Dose Escalation Combination Therapy (BBO-10203)","Participants enrolled in this cohort will receive BBO-11818 in combination with BBO-10203",[13,35],{"label":60,"type":10,"description":11,"interventionNames":61},"Cohort 2a - Dose Expansion Monotherapy",[13],{"label":63,"type":10,"description":16,"interventionNames":64},"Cohort 2b - Dose Expansion Combination (Pembrolizumab)",[13,18],{"label":66,"type":10,"description":21,"interventionNames":67},"Cohort 2c - Dose Expansion Combination Therapy (Pembrolizumab + Cis\u002Fcarboplatin + Pemetrexed)",[13,18,23,24],{"label":69,"type":10,"description":27,"interventionNames":70},"Cohort 2d - Dose Expansion Combination Therapy (Cetuximab ± mFOLFOX6)",[13,29,30],{"label":72,"type":10,"description":33,"interventionNames":73},"Cohort 2e - Dose Expansion Combination Therapy (BBO-10203 + mFOLFOX6)",[13,30,35],{"label":75,"type":10,"description":38,"interventionNames":76},"Cohort 2f - Dose Expansion Combination Therapy (BBO-10203 + Cetuximab)",[13,29,35],{"label":78,"type":10,"description":42,"interventionNames":79},"Cohort 2g - Dose Expansion Combination Therapy (Cetuximab)",[13,29],{"label":81,"type":10,"description":46,"interventionNames":82},"Cohort 2h - Dose Expansion Combination Therapy (mFOLFIRINOX)",[13,48],{"label":84,"type":10,"description":51,"interventionNames":85},"Cohort 2i - Dose Expansion Combination Therapy (Gemcitabine + Nab-paclitaxel)",[13,53,54],{"label":87,"type":10,"description":57,"interventionNames":88},"Cohort 2j - Dose Expansion Combination Therapy (BBO-10203)",[13,35],[90,96,100,104,108,112,116,119,123,127,131],{"type":91,"name":92,"description":93,"armGroupLabels":94,"otherNames":95},"DRUG","BBO-11818","Participants will receive assigned dose of BBO-11818 orally (PO)",[9,15,20,26,32,37,41,45,50,56,60,63,66,69,72,75,78,81,84,87],null,{"type":91,"name":97,"description":98,"armGroupLabels":99,"otherNames":95},"Pembrolizumab","Patients will receive IV pembrolizumab",[15,20,63,66],{"type":91,"name":101,"description":102,"armGroupLabels":103,"otherNames":95},"Platinum chemotherapy (cisplatin or carboplatin)","Patients will receive IV platinum chemotherapy (cisplatin or carboplatin)",[20,66],{"type":91,"name":105,"description":106,"armGroupLabels":107,"otherNames":95},"Pemetrexed","Patients will receive IV pemetrexed",[20,66],{"type":91,"name":109,"description":110,"armGroupLabels":111,"otherNames":95},"Cetuximab","Patients will receive IV cetuximab",[26,37,41,69,75,78],{"type":91,"name":113,"description":114,"armGroupLabels":115,"otherNames":95},"mFOLFOX6","Patients may receive IV mFOLFOX6",[26,69],{"type":91,"name":113,"description":117,"armGroupLabels":118,"otherNames":95},"Patients will receive IV mFOLFOX6",[32,72],{"type":91,"name":120,"description":121,"armGroupLabels":122,"otherNames":95},"BBO-10203","Participants will receive BBO-10203 orally (PO)",[32,37,56,72,75,87],{"type":91,"name":124,"description":125,"armGroupLabels":126,"otherNames":95},"mFOLFIRINOX","Patients will receive IV mFOLFIRINOX",[45,81],{"type":91,"name":128,"description":129,"armGroupLabels":130,"otherNames":95},"Gemcitabine","Patients will receive IV gemcitabine",[50,84],{"type":91,"name":132,"description":133,"armGroupLabels":134,"otherNames":95},"Nab-paclitaxel","Patients will receive IV nab-paclitaxel",[50,84],[136],{"name":5,"role":137,"phone":138,"phoneExt":95,"email":139},"CONTACT","(650) 405-4770","tbbo11818-101ct.gov@bbotx.com",[141,157,169,181,193,206,219,232,245,257,266,279,292,304,316,329,342],{"facility":142,"status":143,"city":144,"state":145,"zip":146,"country":147,"cosmosGeoPoint":148,"geoPoint":153,"contacts":154},"The Angeles Clinic and Research Institute - West Los Angeles Office","RECRUITING","Los Angeles","California","90025","United States",{"type":149,"coordinates":150},"Point",[151,152],-118.24368,34.05223,{"lat":152,"lon":151},[155],{"name":95,"role":137,"phone":156,"phoneExt":95,"email":95},"310-582-7900",{"facility":158,"status":143,"city":159,"state":145,"zip":160,"country":147,"cosmosGeoPoint":161,"geoPoint":165,"contacts":166},"University of California Davis","Sacramento","95817",{"type":149,"coordinates":162},[163,164],-121.4944,38.58157,{"lat":164,"lon":163},[167],{"name":95,"role":137,"phone":168,"phoneExt":95,"email":95},"916-734-5959",{"facility":170,"status":143,"city":171,"state":145,"zip":172,"country":147,"cosmosGeoPoint":173,"geoPoint":177,"contacts":178},"University of California San Diego Moores Cancer Center","San Diego","92037",{"type":149,"coordinates":174},[175,176],-117.16472,32.71571,{"lat":176,"lon":175},[179],{"name":95,"role":137,"phone":180,"phoneExt":95,"email":95},"858-822-6100",{"facility":182,"status":143,"city":183,"state":145,"zip":184,"country":147,"cosmosGeoPoint":185,"geoPoint":189,"contacts":190},"University of California San Francisco Helen Diller Family Comprehensive Cancer Center","San Francisco","94158",{"type":149,"coordinates":186},[187,188],-122.41942,37.77493,{"lat":188,"lon":187},[191],{"name":95,"role":137,"phone":192,"phoneExt":95,"email":95},"415-885-7796",{"facility":194,"status":143,"city":195,"state":196,"zip":197,"country":147,"cosmosGeoPoint":198,"geoPoint":202,"contacts":203},"Yale University","New Haven","Connecticut","06510",{"type":149,"coordinates":199},[200,201],-72.92816,41.30815,{"lat":201,"lon":200},[204],{"name":95,"role":137,"phone":205,"phoneExt":95,"email":95},"203-200-2486",{"facility":207,"status":143,"city":208,"state":209,"zip":210,"country":147,"cosmosGeoPoint":211,"geoPoint":215,"contacts":216},"Moffitt Cancer Center","Tampa","Florida","33612",{"type":149,"coordinates":212},[213,214],-82.45843,27.94752,{"lat":214,"lon":213},[217],{"name":95,"role":137,"phone":218,"phoneExt":95,"email":95},"888-663-3488",{"facility":220,"status":143,"city":221,"state":222,"zip":223,"country":147,"cosmosGeoPoint":224,"geoPoint":228,"contacts":229},"OSF Healthcare Cancer Institute","Peoria","Illinois","61637",{"type":149,"coordinates":225},[226,227],-89.58899,40.69365,{"lat":227,"lon":226},[230],{"name":95,"role":137,"phone":231,"phoneExt":95,"email":95},"309-308-3800",{"facility":233,"status":143,"city":234,"state":235,"zip":236,"country":147,"cosmosGeoPoint":237,"geoPoint":241,"contacts":242},"Massachusetts General Hospital","Boston","Massachusetts","02114",{"type":149,"coordinates":238},[239,240],-71.05977,42.35843,{"lat":240,"lon":239},[243],{"name":95,"role":137,"phone":244,"phoneExt":95,"email":95},"617-724-4000",{"facility":246,"status":143,"city":247,"state":247,"zip":248,"country":147,"cosmosGeoPoint":249,"geoPoint":253,"contacts":254},"NYU Langone Health","New York","10016",{"type":149,"coordinates":250},[251,252],-74.00597,40.71427,{"lat":252,"lon":251},[255],{"name":95,"role":137,"phone":256,"phoneExt":95,"email":95},"646-929-7870",{"facility":258,"status":143,"city":247,"state":247,"zip":259,"country":147,"cosmosGeoPoint":260,"geoPoint":262,"contacts":263},"Columbia University Irving Medical Center","10032",{"type":149,"coordinates":261},[251,252],{"lat":252,"lon":251},[264],{"name":95,"role":137,"phone":265,"phoneExt":95,"email":95},"877-426-5637",{"facility":267,"status":143,"city":268,"state":269,"zip":270,"country":147,"cosmosGeoPoint":271,"geoPoint":275,"contacts":276},"Vanderbilt University Medical Center","Nashville","Tennessee","37232",{"type":149,"coordinates":272},[273,274],-86.78444,36.16589,{"lat":274,"lon":273},[277],{"name":95,"role":137,"phone":278,"phoneExt":95,"email":95},"615-936-8422",{"facility":280,"status":143,"city":281,"state":282,"zip":283,"country":147,"cosmosGeoPoint":284,"geoPoint":288,"contacts":289},"Sarah Cannon Research Institute at Mary Crowley","Dallas","Texas","75230",{"type":149,"coordinates":285},[286,287],-96.80667,32.78306,{"lat":287,"lon":286},[290],{"name":95,"role":137,"phone":291,"phoneExt":95,"email":95},"972-566-3000",{"facility":293,"status":143,"city":294,"state":282,"zip":295,"country":147,"cosmosGeoPoint":296,"geoPoint":300,"contacts":301},"The University of Texas MD Anderson Cancer Center","Houston","77030",{"type":149,"coordinates":297},[298,299],-95.36327,29.76328,{"lat":299,"lon":298},[302],{"name":95,"role":137,"phone":303,"phoneExt":95,"email":95},"877-632-6789",{"facility":305,"status":143,"city":306,"state":282,"zip":307,"country":147,"cosmosGeoPoint":308,"geoPoint":312,"contacts":313},"NEXT Oncology","San Antonio","78229",{"type":149,"coordinates":309},[310,311],-98.49363,29.42412,{"lat":311,"lon":310},[314],{"name":95,"role":137,"phone":315,"phoneExt":95,"email":95},"210-580-9500",{"facility":317,"status":143,"city":318,"state":319,"zip":320,"country":147,"cosmosGeoPoint":321,"geoPoint":325,"contacts":326},"Huntsman Cancer Institute","Salt Lake City","Utah","84112",{"type":149,"coordinates":322},[323,324],-111.89105,40.76078,{"lat":324,"lon":323},[327],{"name":95,"role":137,"phone":328,"phoneExt":95,"email":95},"801-587-7000",{"facility":330,"status":143,"city":331,"state":332,"zip":333,"country":147,"cosmosGeoPoint":334,"geoPoint":338,"contacts":339},"Fred Hutchinson Cancer Center","Seattle","Washington","98109",{"type":149,"coordinates":335},[336,337],-122.33207,47.60621,{"lat":337,"lon":336},[340],{"name":95,"role":137,"phone":341,"phoneExt":95,"email":95},"206-667-5000",{"facility":343,"status":143,"city":344,"state":345,"zip":346,"country":347,"cosmosGeoPoint":348,"geoPoint":352,"contacts":353},"Peter MacCallum Cancer Centre","Melbourne","Victoria","3000","Australia",{"type":149,"coordinates":349},[350,351],144.96332,-37.814,{"lat":351,"lon":350},[354],{"name":95,"role":137,"phone":355,"phoneExt":95,"email":95},"03-8559-5000",{"type":357,"investigatorFullName":95,"investigatorTitle":95,"investigatorAffiliation":95,"oldNameTitle":95,"oldOrganization":95},"SPONSOR","100586569",false,"NCT06917079","BBO-11818 in Adult Subjects With KRAS Mutant Cancer","A Phase 1a\u002F1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects With Advanced KRAS Mutant Cancers","Inclusion Criteria:\n\n* Histologically documented locally advanced and unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor with KRAS G12A, G12C, G12D, G12S, or G12V mutation\n* Measurable disease by RECIST v1.1\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1\n* Life expectancy \\>24 weeks\n* Adequate organ function\n\nExclusion Criteria:\n\n* Malignancy within the last 2 years as specified in the protocol\n* Untreated brain metastases\n\nOther inclusion\u002Fexclusion criteria are specified in the protocol.","ALL","18 Years",{"count":367,"type":368},665,"ESTIMATED","INTERVENTIONAL",[371],"PHASE1","A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.",[374,375,376,377,378,379,380,381,382,383,384,385,386,387],"Non-Small Cell Lung Cancer","NSCLC","PDAC - Pancreatic Ductal Adenocarcinoma","CRC (Colorectal Cancer)","Metastatic Non-Small Lung Cell Cancer","Metastatic Colorectal Cancer (CRC)","KRAS G12A","KRAS G12C","KRAS G12D","KRAS G12S","KRAS G12V","Metastatic Pancreatic Ductal Adenocarcinoma","Advanced Lung Carcinoma","Solid Tumor, Adult",[389,390,391,392,375,393,394,395,396,97,109,397,105,398,399,113,124,128,132],"BBOT","BridgeBio Oncology Therapeutics","Phase1","Phase 1a\u002F1b","CRC","PDAC","Metastatic Cancer","Advanced Cancer","Platinum Chemotherapy","KONQUER","KONQUER-101","2026-05-29",{"date":402,"type":403},"2026-06-02","ACTUAL",{"date":405,"type":403},"2025-03-31",{"date":407,"type":368},"2029-09",{"name":5,"class":6},17]